Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy classified by WHO and marked by cutaneous lesions, bone marrow infiltration, and CNS involvement.
Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a ...
An AI tool that can analyze abnormalities in the shape and form of blood cells, and with greater accuracy and reliability ...
A small label installed on a wire when a giant cargo ship was built may have triggered a chain of events nearly a decade ...
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect ...
Patents in alternative proteins such as cultivated meat, plant-based meat and even insect protein are declining. Innovation ...
In a cohort of Black and Hispanic individuals with relapsing MS, baseline comorbidities had no significant effect on the ...
Per the USDA, 3.5 ounces of 90% lean ground beef contains: ...
One patient dropped out after achieving a notable resolution of the patient’s macrocystic LM. The patient received two doses of TARA-002 with 160 ml aspiration at the first dose, which was reduced to ...
ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3.
Protara Therapeutics (TARA) stock falls as the firm posts mid-stage trial data for its lead asset TARA-002 in children with ...
Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback